0069-0152 : Cytarabine 100 mg/5ml Intrathecal; Intravenous; Subcutaneous Injection


NDC0069-0152
Labeler: Pfizer Laboratories Div Pfizer Inc.
Product Type: Human Prescription Drug
Drug Name: Cytarabine
Dosage Form: Intrathecal; Intravenous; Subcutaneous Injection
Application #: ANDA200915
Rev. Date: 


NDC Package Codes:

  • 0069-0152-02: 10 VIAL IN 1 CARTON (0069‑0152‑02) > 5 ML IN 1 VIAL (0069‑0152‑01)

Active Ingredients:

  • Cytarabine

Dosage Strength:

  • 100 mg/5mL

Pharmaceutical Classes:

  • Nucleic Acid Synthesis Inhibitors [MoA]
  • Nucleoside Metabolic Inhibitor [EPC]

Related Products:

Based on records with the same trade name.
  • 0069-0153 Cytarabine 20 mg/ml Intravenous; Subcutaneous Injection by Pfizer Laboratories Div Pfizer Inc.
  • 0069-0154 Cytarabine 20 mg/ml Intravenous; Subcutaneous Injection by Pfizer Laboratories Div Pfizer Inc.
  • 0069-0155 Cytarabine 2 g/20ml Intrathecal; Intravenous; Subcutaneous Injection by Pfizer Laboratories Div Pfizer Inc.
  • 55390-131 Cytarabine 100 mg/5ml Intrathecal; Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 55390-132 Cytarabine 500 mg/10ml Intrathecal; Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 55390-133 Cytarabine 1 g/10ml Intrathecal; Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 55390-134 Cytarabine 2 g/20ml Intrathecal; Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 55390-806 Cytarabine 100 mg/5ml Intrathecal; Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 55390-807 Cytarabine 500 mg/10ml Intrathecal; Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 55390-808 Cytarabine 1 g/10ml Intrathecal; Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 55390-809 Cytarabine 2 g/20ml Intrathecal; Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 61703-303 Cytarabine 20 mg/ml Intravenous Injection, Solution by Hospira Worldwide, Inc.
  • 61703-304 Cytarabine 20 mg/ml Intravenous; Subcutaneous Solution by Hospira Worldwide, Inc.
  • 61703-305 Cytarabine 20 mg/ml Intrathecal; Intravenous; Subcutaneous Injection, Solution by Hospira Worldwide, Inc.
  • 61703-319 Cytarabine 100 mg/ml Intrathecal; Intravenous; Subcutaneous Injection, Solution by Hospira Worldwide, Inc.
  • 63323-120 Cytarabine 100 mg/ml Intrathecal; Intravenous; Subcutaneous Injection, Solution by App Pharmaceuticals, LLC
  • 67457-452 Cytarabine 2 g/20ml Intrathecal; Intravenous; Subcutaneous Injection by Mylan Institutional LLC
  • 67457-454 Cytarabine 20 mg/ml Intravenous; Subcutaneous Injection by Mylan Institutional LLC
  • 67457-455 Cytarabine 100 mg/5ml Intrathecal; Intravenous; Subcutaneous Injection by Mylan Institutional LLC
  • 67457-615 Cytarabine 2 g/20ml Intrathecal; Intravenous; Subcutaneous Injection by Mylan Institutional LLC
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0069-0152 QR Code

< Prev: 0069-0151Next: 0069-0153 >




Note: The MedsChat® NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.